NDA 212608 · Blueprint Medicines
Ayvakit
Avapritinib · Oral · Kinase Inhibitor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jan 9, 2020
Approved uses
5
Original approval plus efficacy supplements
Registered trials
21
1 Phase 3, 10 recruiting
FAERS reports
12,650
3,692 serious, 380 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 20, 2026.
AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM. ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.3 ) 1.1 PDGFRA Exon 18 Mutation-Positive Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) AYVAKIT ® is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations [see Dosage and Administration (2.2) ] . 1.2 Advanced Systemic Mastocytosis (AdvSM) AYVAKIT is indicated for the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). Limitations of Use : AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L [see Warnings and Precautions (5.1) ] . 1.3 Indolent Systemic Mastocytosis (ISM)...
Mechanism: Avapritinib is a tyrosine kinase inhibitor that targets KIT D816V, PDGFRA and PDGFRA D842 mutants as well as multiple KIT exon 11, 11/17 and 17 mutants with half maximal inhibitory concentrations (IC 50s ) less than 25 nM in biochemical assays. Certain mutations in PDGFRA and KIT can result in the autophosphorylation and constitutive activation of these receptors which can contribute to tumor and mast cell proliferation. Other potential targets for avapritinib include wild type KIT, PDGFRB, and CSFR1. In cellular assays, avapritinib inhibited the autophosphorylation of KIT D816V with an IC 50...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 16, 2026 Supplement 21 · Efficacy OrphanLabelLetter
- May 22, 2023 Supplement 13 · Efficacy · priority review OrphanLabelLetterReview
- Jun 16, 2021 Supplement 6 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
- Jun 16, 2021 Supplement 7 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
- Jan 9, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
5 products under this application
- AYVAKIT · AVAPRITINIB 50MG · TABLET, ORAL · Prescription
- AYVAKIT · AVAPRITINIB 300MG · TABLET, ORAL · Prescription
- AYVAKIT · AVAPRITINIB 100MG · TABLET, ORAL · Prescription
- AYVAKIT · AVAPRITINIB 25MG · TABLET, ORAL · Prescription
- AYVAKIT · AVAPRITINIB 200MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Avapritinib" as an intervention, any sponsor and status, largest first.
- MRD-positive AML Clinical StudyPivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07131059 · 537 participants (planned) · Start May 11, 2024 · Primary completion May 10, 2028
Drug: Ivosidenib; Gilteritinib and 10 more · For: AML, Adult
Sites: Tianjin, China
Children's Hospital of Soochow UniversityAcademic, hospital or other
NCT06221683 · 500 participants (planned) · Start Jan 1, 2024 · Primary completion Dec 2028
Drug: Homoharringtonine; Cytarabine and 8 more · For: AML, Childhood; Acute Myeloid Leukemia
Sites: Hefei, China; Guangzhou, China; Nanning, China · 13 sites in all
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTPivotal-lookingCompleted
Blueprint Medicines CorporationIndustry
NCT03465722 · 476 participants · Start Mar 26, 2018 · Primary completion Mar 9, 2020
Drug: avapritinib; regorafenib · For: GIST
Sites: Phoenix, Arizona; Santa Monica, California; Aurora, Colorado · 114 sites in all
Centre Leon BerardAcademic, hospital or other
NCT04116541 · 455 participants (planned) · Start Jan 28, 2020 · Primary completion Oct 2026
Drug: HDM201; Ribociclib and 6 more · For: Malignant Solid Tumor
Sites: Angers, France; Bordeaux, France; Caen, France · 13 sites in all
- (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisPivotal-lookingActive, not recruiting
Blueprint Medicines CorporationIndustry
NCT03731260 · 251 participants · Start Apr 16, 2019 · Primary completion Jun 23, 2027
Drug: Avapritinib; Placebo · For: Indolent Systemic Mastocytosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Stanford, California · 49 sites in all
Blueprint Medicines CorporationIndustry
NCT02508532 · 250 participants · Start Aug 2015 · Primary completion Mar 6, 2020
Drug: Avapritinib · For: Gastrointestinal Stromal Tumors (GIST); Other Relapsed or Refractory Solid Tumors
Sites: Scottsdale, Arizona; Santa Monica, California; Miami, Florida · 19 sites in all
Blueprint Medicines CorporationIndustry
NCT03580655 · 107 participants · Start Nov 21, 2018 · Primary completion Dec 18, 2024
Drug: Avapritinib · For: Advanced Systemic Mastocytosis; Aggressive Systemic Mastocytosis; Systemic Mastocytosis With an Associated Hematologic Neoplasm and 1 more
Sites: Stanford, California; Chicago, Illinois; Westwood, Kansas · 32 sites in all
Blueprint Medicines CorporationIndustry
NCT02561988 · 86 participants · Start Mar 10, 2016 · Primary completion Oct 5, 2022
Drug: Avapritinib · For: Aggressive Systemic Mastocytosis; Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease; Mast Cell Leukemia and 1 more
Sites: Stanford, California; Denver, Colorado; Atlanta, Georgia · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue1,855
- off label use1,451
- nausea1,306
- diarrhoea1,062
- headache607
- dizziness571
- vomiting549
- swelling face542
- memory impairment532
- asthenia497
- product dose omission issue488
- rash486
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 2 |
| 2020 | 498 |
| 2021 | 1,383 |
| 2022 | 2,358 |
| 2023 | 1,775 |
| 2024 | 2,320 |
| 2025 | 2,496 |
| 2026 | 1,818 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ayvakit (Avapritinib)
2024 spending
$160M
Beneficiaries
547
4,023 claims
Per beneficiary
$292,553
$1,278.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,909,824 |
| 2021 | $15,536,747 |
| 2022 | $32,282,509 |
| 2023 | $55,171,737 |
| 2024 | $160,026,588 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Avapritinib versus Placebo in Indolent Systemic Mastocytosis.
Gotlib J, Castells M, Elberink HO, et al. · NEJM Evid 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
DeAngelo DJ, Radia DH, George TI, et al. · Nat Med 2021 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Heinrich MC, Jones RL, von Mehren M, et al. · Lancet Oncol 2020 · Clinical Trial, Phase I, Multicenter Study
- Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis.
Pilkington H, Smith S, Roskell N, et al. · Future Oncol 2022 · Systematic Review
- Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.
Akin C, Sabato V, Gotlib J, et al. · J Allergy Clin Immunol 2026 · Clinical Trial, Phase II, Multicenter Study
- Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Kang YK, George S, Jones RL, et al. · J Clin Oncol 2021 · Clinical Trial, Phase III, Comparative Study
Sponsor: Blueprint Medicines
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.